Cargando…
Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/ https://www.ncbi.nlm.nih.gov/pubmed/34804848 http://dx.doi.org/10.21037/tau-20-938 |
_version_ | 1784595697547345920 |
---|---|
author | Boegemann, Martin Goebell, Peter Jürgen Woike, Michael Buncke, Johanna Schlack, Katrin Schrader, Andres Jan |
author_facet | Boegemann, Martin Goebell, Peter Jürgen Woike, Michael Buncke, Johanna Schlack, Katrin Schrader, Andres Jan |
author_sort | Boegemann, Martin |
collection | PubMed |
description | BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus treated cohort and compared the results with the physician’s prognosis. METHODS: A German multicenter registry (STAR-TOR) for a/mRCC patients (NCT00700258) was established to evaluate the efficacy and safety of temsirolimus 25 mg weekly in a routine clinical setting. These prospective data were systematically analyzed and followed-up by an independent clinical research organization to compare established prognostic scores (MSKCC, IMDC and Hudes) with the risk assessment by treating physicians based on their medical expertise and match them with survival outcomes. RESULTS: This interim analysis included 547 patients between 02/2008 and 05/2015 in 87 centers. Either prognostic tool resulted in significant and clinically meaningful differentiation between good, intermediate and poor prognosis. However, physician’s prognosis identified more patients with good prognosis (9.1% vs. 1.3%). In patients with good physician’s prognosis and intermediate prognosis by MSKCC, overall survival was nearly doubled compared to consensual intermediate prognosis (26.6 vs. 13.6 months), albeit without reaching statistical significance (P=0.09). For poor prognosis assessed by the physician, MSKCC performed statistically better for differentiation between poor and intermediate prognosis with a median overall survival of 10.3 vs. 5.5 months (P<0.01). CONCLUSIONS: Physician’s prognosis may be able to identify a subset of patients treated with temsirolimus with good prognosis when MSKCC-determines intermediate prognosis while the MSKCC score could identify patients which were falsely placed in the poor risk group by physicians. |
format | Online Article Text |
id | pubmed-8575558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-85755582021-11-18 Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry Boegemann, Martin Goebell, Peter Jürgen Woike, Michael Buncke, Johanna Schlack, Katrin Schrader, Andres Jan Transl Androl Urol Original Article on Management of Advanced Genitourinary Malignancies BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus treated cohort and compared the results with the physician’s prognosis. METHODS: A German multicenter registry (STAR-TOR) for a/mRCC patients (NCT00700258) was established to evaluate the efficacy and safety of temsirolimus 25 mg weekly in a routine clinical setting. These prospective data were systematically analyzed and followed-up by an independent clinical research organization to compare established prognostic scores (MSKCC, IMDC and Hudes) with the risk assessment by treating physicians based on their medical expertise and match them with survival outcomes. RESULTS: This interim analysis included 547 patients between 02/2008 and 05/2015 in 87 centers. Either prognostic tool resulted in significant and clinically meaningful differentiation between good, intermediate and poor prognosis. However, physician’s prognosis identified more patients with good prognosis (9.1% vs. 1.3%). In patients with good physician’s prognosis and intermediate prognosis by MSKCC, overall survival was nearly doubled compared to consensual intermediate prognosis (26.6 vs. 13.6 months), albeit without reaching statistical significance (P=0.09). For poor prognosis assessed by the physician, MSKCC performed statistically better for differentiation between poor and intermediate prognosis with a median overall survival of 10.3 vs. 5.5 months (P<0.01). CONCLUSIONS: Physician’s prognosis may be able to identify a subset of patients treated with temsirolimus with good prognosis when MSKCC-determines intermediate prognosis while the MSKCC score could identify patients which were falsely placed in the poor risk group by physicians. AME Publishing Company 2021-10 /pmc/articles/PMC8575558/ /pubmed/34804848 http://dx.doi.org/10.21037/tau-20-938 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article on Management of Advanced Genitourinary Malignancies Boegemann, Martin Goebell, Peter Jürgen Woike, Michael Buncke, Johanna Schlack, Katrin Schrader, Andres Jan Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title | Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title_full | Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title_fullStr | Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title_full_unstemmed | Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title_short | Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry |
title_sort | assessment of prognosis by established prognosis scores and physicians’ judgement in mrcc patients: an analysis of the star-tor registry |
topic | Original Article on Management of Advanced Genitourinary Malignancies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/ https://www.ncbi.nlm.nih.gov/pubmed/34804848 http://dx.doi.org/10.21037/tau-20-938 |
work_keys_str_mv | AT boegemannmartin assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry AT goebellpeterjurgen assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry AT woikemichael assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry AT bunckejohanna assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry AT schlackkatrin assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry AT schraderandresjan assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry |